# Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

> **NCT01305408** · PHASE3 · COMPLETED · sponsor: **Cephalon** · enrollment: 399 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Armodafinil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01305408
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2016-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01305408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01305408, "Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01305408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*